Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP64353.RAfXUZ2nCIAfZ8oXsLLsQWB_UFh4mVgZJUNntSuxZSVm8130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP64353.RAfXUZ2nCIAfZ8oXsLLsQWB_UFh4mVgZJUNntSuxZSVm8130_provenance.
• NP87742.RA8bNGgXSU98i7-4ohnFu0fE1soMOFwfdvGwudgRxNqNg130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP87742.RA8bNGgXSU98i7-4ohnFu0fE1soMOFwfdvGwudgRxNqNg130_provenance.
• NP74992.RAkeihbshwNpn03bzevnAstzrg0kzv1dquHdYajBKYRIg130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP74992.RAkeihbshwNpn03bzevnAstzrg0kzv1dquHdYajBKYRIg130_provenance.
• assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP53989.RAcZaz--c-cd-0rzVQz8kBymq2nJnk36EusJaE5C98YDs130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP53989.RAcZaz--c-cd-0rzVQz8kBymq2nJnk36EusJaE5C98YDs130_provenance.
• assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP828632.RA6FHaY-LfpKGmpTJaq8GFbAipCoO6uPQw_pcr67G-ZFE130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828632.RA6FHaY-LfpKGmpTJaq8GFbAipCoO6uPQw_pcr67G-ZFE130_provenance.
• NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.
• NP107577.RArItcI3jBbSyUhqUBJN4bz6FyvnTPP6KJtKSoXxk02zs130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP107577.RArItcI3jBbSyUhqUBJN4bz6FyvnTPP6KJtKSoXxk02zs130_provenance.
• NP83386.RArbYsUMj_SnORGMEuaILxt6u_GGj3PuFPQWzRBxnv6xE130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP83386.RArbYsUMj_SnORGMEuaILxt6u_GGj3PuFPQWzRBxnv6xE130_provenance.
• NP173634.RAZCb62-GMmQTc2UlGjv3Wj-SWHiPQDeGxs9p8Ryk5TkE130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173634.RAZCb62-GMmQTc2UlGjv3Wj-SWHiPQDeGxs9p8Ryk5TkE130_provenance.
• NP173635.RAVe1ctbpHsrM68bYgNMpu6qrPfddtyARad37zpzj-GgY130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173635.RAVe1ctbpHsrM68bYgNMpu6qrPfddtyARad37zpzj-GgY130_provenance.
• NP173636.RAfVU9GRJTGYA3qaDSL_zS5EA29YQCtpQQbLBN1P5KkB0130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173636.RAfVU9GRJTGYA3qaDSL_zS5EA29YQCtpQQbLBN1P5KkB0130_provenance.
• NP173637.RAWSBYaOaUuZ_QCsYCgDQOb26PEiSfPPN4yumUnI-k9H4130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173637.RAWSBYaOaUuZ_QCsYCgDQOb26PEiSfPPN4yumUnI-k9H4130_provenance.
• NP78947.RAAPTFv9Sc3IBiaM9KaR123KEky3c9ZZdm0eV2c7UR-hU130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP78947.RAAPTFv9Sc3IBiaM9KaR123KEky3c9ZZdm0eV2c7UR-hU130_provenance.
• NP173632.RAlMiWxoRcq55papyu_hlIc5oVSyIIx4ZbhWrXMUxgOZE130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173632.RAlMiWxoRcq55papyu_hlIc5oVSyIIx4ZbhWrXMUxgOZE130_provenance.
• NP57274.RALcT1Gj5gbGchC7Mc90jvgocZ8hN9sVROHYnlfJnTsQ0130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP57274.RALcT1Gj5gbGchC7Mc90jvgocZ8hN9sVROHYnlfJnTsQ0130_provenance.